Pharmacokinetic and pharmacodynamic modeling of pegylated-interferon alfa

被引：0
|
作者：
Dimova, Rositsa B.
Talal, Andrew H. [1 ]
机构：
[1] Weill Cornell Med Coll, Ctr Study Hepatitis C, New York, NY 10065 USA
来源：
JOURNAL OF HEPATOLOGY | 2010年 / 53卷 / 03期
关键词：
HEPATITIS-C VIRUS; INFECTED PATIENTS; HCV; RIBAVIRIN; KINETICS; HIV; RESPONSES; EFFICACY; DYNAMICS; THERAPY;
D O I：
10.1016/j.jhep.2010.04.014
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：418 / 420
页数：3
相关论文
共 50 条
  • [21] Efficacy and safety of pegylated-interferon α-2a in hemodialysis patients with chronic hepatitis C
    Ayaz, Celal
    Celen, Mustafa Kemal
    Yuce, Ugur Nedim
    Geyik, Mehmet Faruk
    WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (02) : 255 - 259
  • [22] A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects
    Zheng, Li
    Li, Mao Ping
    Gou, Zhong Ping
    Wang, Ying
    Xu, Nan
    Cai, Yong Ming
    Luo, Hua
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 79 (04) : 650 - 659
  • [23] Efficacy and safety of pegylated-interferon α-2a in hemodialysis patients with chronic hepatitis C
    Celal Ayaz
    Mustafa Kemal Celen
    Ugur Nedim Yuce
    Mehmet Faruk Geyik
    World Journal of Gastroenterology, 2008, (02) : 255 - 259
  • [24] Modeling viral and drug kinetics: Hepatitis C virus treatment with pegylated interferon alfa-2b
    Powers, KA
    Dixit, NM
    Ribeiro, RM
    Golia, P
    Talal, AH
    Perelson, AS
    SEMINARS IN LIVER DISEASE, 2003, 23 : 13 - 18
  • [25] Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin
    Jablonowska, Elzieta
    Piekarska, Anna
    Koslinska-Berkan, Ewa
    Omulecka, Aleksandra
    Szymanska, Bozena
    Wojcik, Kamila
    ACTA BIOCHIMICA POLONICA, 2012, 59 (03) : 333 - 337
  • [26] Pityriasis Rosea Associated with Pegylated Interferon Alfa and Ribavirin Treatment in a Patient with Chronic Hepatitis C
    Guner, Rahmet
    Keske, Siran
    Hasanoglu, Imran
    Tasyaran, Mehmet
    BALKAN MEDICAL JOURNAL, 2013, 30 (02) : 253 - 254
  • [27] Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C
    Rao, P. N.
    Koshy, Abraham
    Philip, Jacob
    Premaletha, Narayanan
    Varghese, Joy
    Narayanasamy, Krishnasamy
    Mohindra, Samir
    Pai, Nitin Vikas
    Agarwal, Manoj Kumar
    Konar, Ashoknanda
    Vora, Hasmukh B.
    WORLD JOURNAL OF HEPATOLOGY, 2014, 6 (07) : 520 - 526
  • [28] Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C
    PN Rao
    Abraham Koshy
    Jacob Philip
    Narayanan Premaletha
    Joy Varghese
    Krishnasamy Narayanasamy
    Samir Mohindra
    Nitin Vikas Pai
    Manoj Kumar Agarwal
    Ashokna Konar
    Hasmukh B Vora
    World Journal of Hepatology, 2014, (07) : 520 - 526
  • [29] Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers
    Costa, Marisa Boff
    Picon, Paulo Dornelles
    Sander, Guilherme Becker
    Cuni, Hugo Nodarse
    Silva, Carmen Valenzuela
    Meireles, Rolando Paez
    Magalhaes Andrade Goes, Ana Carolina
    Batoreu, Nadia Maria
    de Sousa Maia, Maria de Lourdes
    Albuquerque, Elizabeth Maciel
    de Souza Matos, Denise Cristina
    Saura, Pedro Lopez
    BMC PHARMACOLOGY & TOXICOLOGY, 2018, 19
  • [30] Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon
    Boglione, Lucio
    Cusato, Jessica
    Cariti, Giuseppe
    Di Perri, Giovanni
    D'Avolio, Antonio
    ANTIVIRAL RESEARCH, 2016, 136 : 32 - 36
12345